newsfilter
← Earnings
Earnings Releases·

Personalis — Third Quarter 2026 Earnings Summary

  • Total revenue reached $25.6 million in Q3 2026, a significant increase from $14.5 million in the prior year period, driven by a 200% rise in clinical test volume to 13,157 and a full quarter of Medicare-covered IO test volume.
  • Net loss widened to $33.8 million ($0.32 per share) compared to $21.7 million ($0.24 per share) in Q3 2025, while total costs and expenses rose to $61.1 million from $37.8 million.
  • The company announced it will cease providing financial guidance and quarterly conference calls following the July 20, 2026, merger agreement with Tempus AI, Inc.
  • Strategic progress includes the launch of the NeXT Personal® Real-Time Variant Tracker™ and positive pre-interim clinical data from the B-STRONGER-1 study, alongside a cash position of approximately $190.6 million.
Company
PERSONALIS INC
Sector
Healthcare
Industry
Diagnostics & Research